Sanofi Signs a License Agreement with Biond for BND-22
Shots:
- Biond to receive $125M up front in cash and will be eligible to receive ~$1B+ as development- regulatory & commercial milestones- along with royalties on sales of the therapy
- Biond will lead P-Ia study of BND-22- assessing its safety & tolerability as a single agent and in combination with approved cancer therapies as well as exploring potential associations b/w BND-22 anti-tumor activity- select tumor and blood-based biomarkers. Sanofi will be further responsible for clinical development and commercialization of BND-22
- BND-22 is a humanized IgG4- antagonist Ab targeting ILT2 receptor in development for solid tumors. The first P-Ia study of BND-22 is anticipated to start by mid-2021
Ref: PRNewswire | Image: Sanofi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
